Cutera Inc Stock Price, News & Analysis

Cutera, Inc. (Nasdaq: CUTR) reported second-quarter 2022 revenue of $64.2 million, reflecting a 10% year-over-year increase. This growth was supported by strong demand in capital equipment and consumables. Despite a GAAP net loss of $47.3 million and increased operating expenses of $45.1 million, the company maintains its 2022 revenue guidance of $255 million to $260 million. Key developments include the successful initial launch of its AviClear treatment for acne, with over 50 devices activated. The company anticipates adding more than 100 AviClear devices in Q3 2022.

Cutera, Inc. (NASDAQ: CUTR) will report its second-quarter financial results after market close on August 4, 2022. A conference call to discuss these results will follow at 1:15 p.m. PT (4:15 p.m. ET) on the same day. Investors can join the call by dialing 1-800-319-4610 domestically or +1-631-891-4304 internationally. The call will also be available via webcast through Cutera's Investor Relations page, with a replay available about one hour after the call concludes.

Cutera, Inc. has announced the Health Canada clearance of AviClear, the first energy device approved in North America for treating mild to severe acne. Following its FDA clearance in March 2022, AviClear demonstrates long-term efficacy by reducing existing acne and minimizing future breakouts after three treatment sessions. The device targets sebocytes to control sebum production, addressing a leading cause of acne. AviClear's expansion into Canada promises to enhance acne care for many patients.

Cutera has launched AviClear, the first FDA-cleared energy-based device for treating acne, across North America. A survey shows 90% of acne sufferers believe clear skin would significantly enhance their lives. Many respondents reported missing important life events due to their condition. The CEO emphasized the emotional impact of acne and expressed enthusiasm for AviClear's potential to help patients regain confidence. The company is planning a measured expansion of AviClear providers throughout 2022, aiming to redefine acne treatment.

Cutera, Inc. announced the pricing of $210 million in 2.25% convertible senior notes due 2028. The offering is aimed at qualified institutional buyers, with a closing date expected on May 27, 2022. The notes bear a 2.25% interest rate, maturing on June 1, 2028, and convertible into cash or shares of Cutera's common stock at the company's discretion. The offering is projected to generate approximately $202.8 million in net proceeds, intended for capped call transactions, Notes Exchange, and general corporate purposes, including potential acquisitions.

Cutera, Inc. (CUTR) plans to offer up to $200 million in convertible senior notes due 2028, pending market conditions, through a private placement for qualified institutional buyers. An additional $30 million may be offered if initial purchasers exercise their option. The funds will primarily support capped call transactions, a notes exchange, and general corporate purposes, including potential acquisitions. Notably, affiliated entities may purchase up to $10 million in the notes. These notes will be unsecured and convertible into cash and/or Cutera's common stock.

Cutera (CUTR) reported a strong 17% revenue growth for Q1 2022, reaching $58 million. This increase rose to 21% when adjusted for constant currency, fueled by robust North American performance. Capital Equipment revenue surged by 29% to $36.5 million. However, operating expenses escalated to $44.9 million, resulting in a GAAP net loss of $15.1 million, compared to a slight loss in the prior year. The company maintained its full-year revenue guidance of $255-$260 million, indicating a growth rate of 13%-15% without accounting for AviClear contributions.

Cutera Inc. (CUTR) announced the presentation of clinical data for its FDA-cleared device AviClear at the American Society for Laser Medicine and Surgery meeting held between April 27-30, 2022, in San Diego, CA. AviClear is a 1726 nm laser designed to treat mild, moderate, and severe acne. The device's efficacy and safety were showcased through two oral and four poster presentations by expert physicians. Following FDA clearance in March 2022, AviClear is set for national availability in the U.S. in 2022, with select treatments starting in April.

Cutera, Inc. (NASDAQ: CUTR), a prominent provider of aesthetic and dermatology solutions, will announce its first-quarter 2022 financial results on May 10, 2022, after market close. A conference call to discuss these results is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on the same day. Interested parties can join by calling 1-800-381-7839 (domestic) or +1-416-981-0157 (international) using Conference ID: 22017471. The call will also be available as a live webcast on Cutera's website shortly after the call concludes.